BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/11/2014 2:06:00 PM | Browse: 849 | Download: 707
Publication Name World Journal of Clinical Oncology
Manuscript ID 8264
Country Canada
Received
2014-01-13 08:57
Peer-Review Started
2014-02-08 11:47
To Make the First Decision
2014-03-12 17:08
Return for Revision
2014-04-21 16:07
Revised
2014-04-30 02:10
Second Decision
2014-07-14 17:02
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-07-14 17:24
Articles in Press
2014-07-14 17:27
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-11-19 11:03
Publish the Manuscript Online
2014-12-11 14:23
ISSN 2218-4333 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Retrospective Study
Article Title Competing risks of death in younger and older postmenopausal breast cancer patients
Manuscript Source Invited Manuscript
All Author List Judy-Anne W Chapman, Kathleen I Pritchard, Paul E Goss, James N Ingle, Hyman B Muss, Susan F Dent, Ted A Vandenberg, Brian Findlay, Karen A Gelmon, Carolyn F Wilson, Lois E Shepherd and Michael N Pollak
Funding Agency and Grant Number
Funding Agency Grant Number
Canadian Cancer Society through a grant to the NCIC Clinical Trials Group from the Canadian Cancer Society Research Institute
Novartis provided the NCIC CTG MA.14 drug octreotide LAR
Corresponding Author Judy-Anne W Chapman, PhD, Senior Biostatistician, NCIC Clinical Trials Group, Queen's University, 10 Stuart Street, Kingston, ON, K7L 3N6, Canada. jchapman@ctg.queensu.ca
Key Words Breast cancer; Postmenopausal; Hormone receptor positive; Competing risks; Tamoxifen; Octreotide LAR
Core Tip With earlier detection and improved therapies, patients with early breast cancer simultaneously face multiple health risks; 54% of women ≥ 70 years at diagnosis died from other causes. Octreotide LAR, an early drug targeting the insulin pathway, might have affected both breast and other cause mortality. We demonstrated a method of jointly assessing the impact of therapy and baseline patient characteristics on multiple causes of death. Older patients with higher body mass index experienced more other cause mortality, while women with smaller hormone receptor positive tumours and less lymph node involvement were less likely to die from breast cancer.
Publish Date 2014-12-11 14:23
Citation Chapman JAW, Pritchard KI, Goss PE, Ingle JN, Muss HB, Dent SF, Vandenberg TA, Findlay B, Gelmon KA, Wilson CF, Shepherd LE, Pollak MN. Competing risks of death in younger and older postmenopausal breast cancer patients. World J Clin Oncol 2014; 5(5): 1088-1096
URL http://www.wjgnet.com/2218-4333/full/v5/i5/1088.htm
DOI http://dx.doi.org/10.5306/wjco.v5.i5.1088
Full Article (PDF) WJCO-5-1088.pdf
Full Article (Word) WJCO-5-1088.doc
Manuscript File 8264-Review.doc
Answering Reviewers 8264-Answering reviewers.pdf
Copyright License Agreement 8264-Copyright assignment.pdf
Peer-review Report 8264-Peer review(s).pdf
Scientific Misconduct Check 8264-CrossCheck.jpg
Scientific Editor Work List 8264-Scientific editor work list.pdf